Xenikos raises $30M series B for GVHD

Xenikos B.V. (Nijmegen, the Netherlands) raised $30 million in a tranched series B round co-led by new investors Medicxi and RA Capital.

In early 2019, the company plans to start Phase III testing in the U.S. and EU of lead candidate T-Guard to treat steroid-resistant, acute graft-versus-host disease (GvHD)...